Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birabresib (MK-8628) in Relapsed/Refractory AML and DLBCL
NCT02698189Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of birabresib in acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) (2 cohorts), sponsored by Merck & Co. Primary endpoint: Percentage of Participants With a Dose Limiting Toxicity (DLT) up to 21 days. Started May 2016; status: terminated.
02
Drugs
birabresib
03
Conditions
acute myeloid leukemia (AML)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02698189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698189.